TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36432510

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 10,000 IU/day for 8 weeks followed by 1000 IU/day for 4 weeks
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 50,000 IU/week for 12 weeks
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 100,000 IU every other week for 12 weeks
Number of subjects: 75
Study: 33985845

Group type: EXPERIMENTAL
Intervention: Interactive group psychoeducation
Number of subjects: 58

Group type: COMPARATOR
Intervention: Delay control group
Number of subjects: 58
Study: 32493289

Group type: EXPERIMENTAL
Intervention: Anteromedial (AM) drilling
Number of subjects: 300

Group type: COMPARATOR
Intervention: Transtibial (TT) drilling
Number of subjects: 300
Study: 34767068

Group type: EXPERIMENTAL
Intervention: Pretreatment DCE‐MRI
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Nomogram based on DCE‐MRI findings
Number of subjects: 108
Study: 34294537

Group type: EXPERIMENTAL
Intervention: X-ray
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 24
Study: 35665728

Group type: EXPERIMENTAL
Intervention: Nintedanib (switch group)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Nintedanib plus pirfenidone (combination group)
Number of subjects: 7
Study: 33177138

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 226

Group type: COMPARATOR
Intervention: No discontinuation
Number of subjects: 226

Group type: COMPARATOR
Intervention: Partial discontinuation
Number of subjects: 226
Study: 33289436

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 0
Study: 33248570

Group type: EXPERIMENTAL
Intervention: 200 U/kg glucose oxidase (GOD)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 30 mg/kg virginiamycin (antibiotic)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Basal diet (control)
Number of subjects: 144
Study: 33433147

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided trigger point injections (TPI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ultrasound-guided transversus abdominis plane (TAP) block
Number of subjects: 60
Study: 32366214

Group type: EXPERIMENTAL
Intervention: Individualized intervention based on comprehensive geriatric assessment
Number of subjects: 242

Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 242
Study: 34424337

Group type: EXPERIMENTAL
Intervention: MAPS-6
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: MAPS-12
Number of subjects: 603

Group type: COMPARATOR
Intervention: Standard Treatment
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: NRT
Number of subjects: 603
Study: 34051626

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Present-Centered Therapy (PCT)
Number of subjects: 267
Study: 32164579

Group type: EXPERIMENTAL
Intervention: Ipilimumab with temozolomide (Arm A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Temozolomide alone (Arm B)
Number of subjects: 120
Study: 35088616

Group type: EXPERIMENTAL
Intervention: Questionnaires administered via paper booklets, interactive voice response system, or tablet web survey
Number of subjects: 1830

Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes Measurement Information System scales
Number of subjects: 1830
Study: 34447897

Group type: EXPERIMENTAL
Intervention: Kusamala Program (4-day hospital-based counseling program for caregivers of children with SAM)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Comparison arm (control group)
Number of subjects: 172
Study: 36029969

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1097
Study: 32896653

Group type: EXPERIMENTAL
Intervention: Viaskin-PT 25 μg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Viaskin-PT 50 μg
Number of subjects: 102

Group type: COMPARATOR
Intervention: Laser + Viaskin-placebo
Number of subjects: 102
Study: 36460293

Group type: EXPERIMENTAL
Intervention: rTMS-tDCS
Number of subjects: 84

Group type: COMPARATOR
Intervention: single-tDCS
Number of subjects: 84

Group type: COMPARATOR
Intervention: sham
Number of subjects: 84

Group type: COMPARATOR
Intervention: single-rTMS
Number of subjects: 84
Study: 33794969

Group type: EXPERIMENTAL
Intervention: Vivomixx® probiotic (10 billion CFU/ml, 1 ml/day for 30 days)
Number of subjects: 6144

Group type: COMPARATOR
Intervention: Placebo (organoleptically similar)
Number of subjects: 6144
Study: 34860350

Group type: EXPERIMENTAL
Intervention: Text-based scheduled gradual reduction (SGR) intervention
Number of subjects: 0
Study: 32791618

Group type: EXPERIMENTAL
Intervention: Immersive virtual reality assisted vestibular rehabilitation training (VRT)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Conventional vestibular rehabilitation training (VRT)
Number of subjects: 98
Study: 35939096

Group type: EXPERIMENTAL
Intervention: COVID Impact survey follow-up after approximately 11.4 months
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: HADS-depression scale
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: HADS-anxiety scale
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Predictors of mental well-being
Number of subjects: 74
Study: 34379915

Group type: EXPERIMENTAL
Intervention: mRNA-1273 vaccine (100 µg, two injections, 28 days apart)
Number of subjects: 3732

Group type: EXPERIMENTAL
Intervention: mRNA-1273 vaccine
Number of subjects: 3732

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3732
Study: 36206951

Group type: EXPERIMENTAL
Intervention: Multilevel, faith-based intervention linking Catholic parishes to local parks
Number of subjects: 1204
Study: 34349370

Group type: EXPERIMENTAL
Intervention: LMA Protector™
Number of subjects: 0

Group type: COMPARATOR
Intervention: LMA Supreme™
Number of subjects: 0
Study: 35439548

Group type: EXPERIMENTAL
Intervention: WW+ginger (ginger footbaths)
Number of subjects: 28

Group type: COMPARATOR
Intervention: WW (warm water footbaths)
Number of subjects: 28
Study: 34269848

Group type: EXPERIMENTAL
Intervention: MB02 (3 mg/kg IV dose)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Reference bevacizumab (3 mg/kg IV dose)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: MB02
Number of subjects: 48

Group type: COMPARATOR
Intervention: Reference bevacizumab
Number of subjects: 48
Study: 35526047

Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sugammadex
Number of subjects: 0
Study: 33601928

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 32921196

Group type: EXPERIMENTAL
Intervention: Dietary intervention (biannual counseling based on Nordic Nutrition Recommendations)
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Dietary intervention (including dietary cholesterol as an additional target)
Number of subjects: 877
Study: 35405955

Group type: EXPERIMENTAL
Intervention: Isotretinoin combined with evening primrose oil (4 × 510 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Isotretinoin
Number of subjects: 50
Study: 32771276

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg IV every 3 weeks and PLD 40 mg/m2 IV every 4 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Pembrolizumab and PLD combination therapy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 26
Study: 35361328

Group type: EXPERIMENTAL
Intervention: FKB238
Number of subjects: 99

Group type: COMPARATOR
Intervention: EU-bevacizumab
Number of subjects: 99

Group type: COMPARATOR
Intervention: US-bevacizumab
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: All treatments (FKB238, EU-bevacizumab, US-bevacizumab)
Number of subjects: 99
Study: 33761573

Group type: EXPERIMENTAL
Intervention: Hypothermic machine perfusion (HMP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normothermic machine perfusion (NMP)
Number of subjects: 0
Study: 32159313

Group type: COMPARATOR
Intervention: 5 Hz rTMS
Number of subjects: 41

Group type: COMPARATOR
Intervention: iTBS
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 5 Hz rTMS and iTBS
Number of subjects: 41
Study: 35398854

Group type: EXPERIMENTAL
Intervention: Face-to-face motivational interviewing (MI)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Phone call motivational interviewing (MI)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study: 32930336

Group type: EXPERIMENTAL
Intervention: 3-week adaptive gamified Go/NoGo inhibitory control training (ICT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2-back working-memory training
Number of subjects: 0
Study: 32469906

Group type: EXPERIMENTAL
Intervention: Training intervention using video, poster, and leaflet
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Training intervention using leaflets
Number of subjects: 452
Study: 35880650

Group type: EXPERIMENTAL
Intervention: COMP-MST
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: COMP
Number of subjects: 52

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 52
Study: 33838478

Group type: EXPERIMENTAL
Intervention: Pulsed-field gel electrophoresis (PFGE)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Whole-genome analysis
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Multilocus sequence typing (MLST)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Rarefaction analysis
Number of subjects: 200
Study: 33729323

Group type: EXPERIMENTAL
Intervention: Chahuang ointment
Number of subjects: 171

Group type: COMPARATOR
Intervention: Mucopolysaccharide Polysulfate cream
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 171
Study: 33303446

Group type: EXPERIMENTAL
Intervention: M‐MIST plus Bio‐Oss Collagen
Number of subjects: 40

Group type: COMPARATOR
Intervention: M‐MIST
Number of subjects: 40
Study: 33803073

Group type: EXPERIMENTAL
Intervention: Multilevel multicomponent (MLMC) intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sub-components of the MLMC intervention
Number of subjects: 0
Study: 33161472

Group type: EXPERIMENTAL
Intervention: Sunscreen formulations with nanostructured lipid carriers (NLCs) containing quercetin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sunscreen formulations without antioxidants
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sunscreen formulations with antioxidants in free form
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sunscreen formulations with antioxidants loaded in NLCs
Number of subjects: 60
Study: 34197060

Group type: EXPERIMENTAL
Intervention: Anodic transcranial direct current stimulation plus resistance training (a‐tDCS + RT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham plus resistance training (Sham + RT)
Number of subjects: 28
Study: 32452208

Group type: EXPERIMENTAL
Intervention: HGH treatment
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 19
Study: 33170109

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (N=7,782)
Number of subjects: 15762

Group type: COMPARATOR
Intervention: Usual care control (N=7,981)
Number of subjects: 15762
Study: 33334577

Group type: EXPERIMENTAL
Intervention: Mobile dermoscopy-enhanced self-skin examination
Number of subjects: 234

Group type: COMPARATOR
Intervention: Naked-eye skin self-examination
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Overall diagnostic concordance
Number of subjects: 234
Study: 34089371

Group type: EXPERIMENTAL
Intervention: Children
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Adult joggers/runners
Number of subjects: 89
Study: 32496921

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 546
Study: 33000891

Group type: EXPERIMENTAL
Intervention: Long-term injectable opioid agonist treatment with diacetylmorphine (DAM)
Number of subjects: 22
Study: 36456622

Group type: COMPARATOR
Intervention: tDCS (transcranial direct current stimulation) combined with cognitive training
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: rs-dFC state 4
Number of subjects: 25

Group type: COMPARATOR
Intervention: rs-sFC measure
Number of subjects: 25
Study: 34570203

Group type: EXPERIMENTAL
Intervention: Psychosocial aftercare (PAC) program
Number of subjects: 419

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 419
Study: 33153350

Group type: EXPERIMENTAL
Intervention: Action Observation (AO) in patient group (PG)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Motor Imagery (MI) in patient group (PG)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Action Observation (AO) in patient group (PG) with greater levels of kinesiophobia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Action Observation (AO) in control group (CG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Motor Imagery (MI) in control group (CG)
Number of subjects: 60
Study: 32723393

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 36494644

Group type: EXPERIMENTAL
Intervention: Multi-arm multi-stage design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian response adaptive randomization design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptive phase IIc designs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Seamless designs
Number of subjects: 0
Study: 33764619

Group type: EXPERIMENTAL
Intervention: CX-8998 (10 mg twice daily)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 33105261

Group type: EXPERIMENTAL
Intervention: Interactive speech intelligibility task using Modified Rhyme Test in noisy environments.
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Measurement of signal-to-noise ratio (SNR) during speech intelligibility task.
Number of subjects: 174
Study: 35365958

Group type: EXPERIMENTAL
Intervention: Daily administration of low-dose methotrexate (12.5 mg divided in 5 days/week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weekly administration of low-dose methotrexate (12.5 mg once per week)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both daily and weekly administration of low-dose methotrexate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily and weekly administration of low-dose methotrexate
Number of subjects: 0
Study: 34132789

Group type: EXPERIMENTAL
Intervention: Genetic risk score (GRS) of RA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetically determined RA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RA in Asian population
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibodies against citrullinated proteins-positive RA
Number of subjects: 0
Study: 32515134

Group type: EXPERIMENTAL
Intervention: Wellness Watch (WW)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Both conditions (WW and PW)
Number of subjects: 42
Study: 616038469

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Number of subjects: 35

Group type: COMPARATOR
Intervention: Topical brinzolamide bid for 2 weeks followed by intravitreal bevacizumab
Number of subjects: 35

Group type: COMPARATOR
Intervention: Brinzolamide bid for 4 weeks
Number of subjects: 35
Study: 36164983

Group type: EXPERIMENTAL
Intervention: Cocoa flavanol (CF) 1350 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 34162644

Group type: EXPERIMENTAL
Intervention: CPAP 10 cmH2O
Number of subjects: 200

Group type: COMPARATOR
Intervention: CPAP 7 cmH2O
Number of subjects: 200
Study: 32701665

Group type: EXPERIMENTAL
Intervention: Oral 17-beta-estradiol 0.5 mg/d
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 to 20 mg/d
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Yoga/Aerobic exercise
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR 75 mg/d
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids 1.8 g/d
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1005
Study: 35121216

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab injection (0.5 mg) every 3 months for 24 months
Number of subjects: 108

Group type: COMPARATOR
Intervention: Sham injection every 3 months for 24 months
Number of subjects: 108
Study: 34278942

Group type: EXPERIMENTAL
Intervention: biofeedback at high stroke rates (BFb90)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: biofeedback at low stroke rates (BFb60)
Number of subjects: 30

Group type: COMPARATOR
Intervention: control at high stroke rates
Number of subjects: 30

Group type: COMPARATOR
Intervention: control at low stroke rates
Number of subjects: 30
Study: 33033047

Group type: EXPERIMENTAL
Intervention: Cangrelor administered IV periprocedurally
Number of subjects: 38
Study: 34520130

Group type: EXPERIMENTAL
Intervention: Inhaled bronchodilators (6 weeks)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Inhaled bronchodilators + inhaled corticosteroids (ICS) (12 weeks)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Inhaled bronchodilators + ICS
Number of subjects: 31
Study: 33129298

Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP)
Number of subjects: 64
Study: 36405425

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 32119677

Group type: EXPERIMENTAL
Intervention: Evidence-based risk estimates provided to neurosurgeons for treatment recommendations.
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group (no evidence-based risk estimates provided).
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Evidence-based risk estimates provided to neurosurgeons for prognostic beliefs.
Number of subjects: 139
Study: 36026559

Group type: EXPERIMENTAL
Intervention: Platelet lysate (PL) - sub acromial injections every week for a total of 3 injections
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ketorolac tromethamine - two injections once every two weeks
Number of subjects: 40
Study: 32851660

Group type: EXPERIMENTAL
Intervention: Genetically raised LDL cholesterol levels
Number of subjects: 121885

Group type: EXPERIMENTAL
Intervention: Higher genetically predicted HDL cholesterol levels
Number of subjects: 121885

Group type: EXPERIMENTAL
Intervention: Genetically predicted increased LDL cholesterol levels
Number of subjects: 121885

Group type: EXPERIMENTAL
Intervention: Triglycerides
Number of subjects: 121885
Study: 35049407

Group type: EXPERIMENTAL
Intervention: Soft cushioning shoes
Number of subjects: 848

Group type: COMPARATOR
Intervention: Hard cushioning shoes
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: General running biomechanics
Number of subjects: 848
Study: 34515977

Group type: EXPERIMENTAL
Intervention: Envarsus (LCPT)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard body weight-based approach
Number of subjects: 69
Study: 36324156

Group type: EXPERIMENTAL
Intervention: Sit-stand desk (SSD) intervention
Number of subjects: 0
Study: 34570004

Group type: EXPERIMENTAL
Intervention: Web-based training, four-session telephone follow-up, and one text message weekly
Number of subjects: 64

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 64
Study: 33205347

Group type: EXPERIMENTAL
Intervention: Dating Matters®: Strategies to Promote Healthy Teen Relationships
Number of subjects: 0

Group type: COMPARATOR
Intervention: Another evidence‐based program
Number of subjects: 0
Study: 32070419

Group type: EXPERIMENTAL
Intervention: Environmental cleaning bundle intervention
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 11
Study: 35008009

Group type: COMPARATOR
Intervention: Serum BAFF levels in CRSwNP patients
Number of subjects: 120

Group type: COMPARATOR
Intervention: Serum BAFF levels in recurrence group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Serum BAFF as a predictive biomarker
Number of subjects: 120
Study: 34014922

Group type: EXPERIMENTAL
Intervention: Active TENS (F = 100 Hz, pulse duration = 200 μs, for 30 min)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo TENS (same parameters as active TENS, but for only 30 s, then ramped off over 15 s)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Educational booklet (instructions about health promotion and education actions related to PD)
Number of subjects: 174
Study: 33007981

Group type: EXPERIMENTAL
Intervention: JRE + dark chocolate supplementation (JD)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: JRE + white chocolate (JW)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: dark chocolate supplementation (DS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 48
Study: 34105104

Group type: EXPERIMENTAL
Intervention: Insomnia only
Number of subjects: 253

Group type: COMPARATOR
Intervention: OSA only
Number of subjects: 253
Study: 34143642

Group type: EXPERIMENTAL
Intervention: Timing of critical care nutrition
Number of subjects: 0
Study: 32883309

Group type: EXPERIMENTAL
Intervention: Immediate programmed cryotherapy and continuous passive motion (CPM) applied within 1 hour after surgery.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no cryotherapy or CPM).
Number of subjects: 60
Study: 35468803

Group type: EXPERIMENTAL
Intervention: ANI group (goal-directed analgesia targeting 50-80 ANI range with prophylactic morphine if ANI < 50)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care only (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ANI group (goal-directed analgesia)
Number of subjects: 0
Study: 33465098

Group type: EXPERIMENTAL
Intervention: Insecticide-treated screening (ITS)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control (absence of ITS)
Number of subjects: 2
Study: 34755655

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA, 1.6 g/day)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA, 0.7 g/day)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 34279598

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 35

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 35
Study: 33106976

Group type: EXPERIMENTAL
Intervention: Couple-based supportive communication (CSC) intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 20